Curcumin and pomegrantes - new hope for Alzheimer’s prevention?
New research at University of Warwick will test how curcumin kick-starts the brain’s cleansing of damaging plaques and cells.
New research at the University of Warwick is underway to prove how well curcumin and pomegranates can hack autophagy to prevent Alzheimer’s disease.
The hope is that the studies will show that this naturally-occurring compounds found especially in turmeric can - when combined with intermittent fasting - prevent the build-up of damaging protein fragments that form between nerve cells in the brain and cause neurological problems.
It’s thought that these fragments may be produced as part of the brain’s self-defence process and that their presence is a symptom of the disease. In a healthy brain, these fragments are broken down and eliminated, but problems occur if they begin to accumulate and form the hard, insoluble amyloid plaques known to be one of the major symptoms of Alzheimer's disease.
Previous related research at the Chinese University of Hong Kong in 2008 found that Biocurcumax, a patented extract available as a food supplement, helped prevent further build-up of these amyloid plaques and subsequently was approved by the FDA for investigational Therapy.
The importance of curcumin seems to hinge on its ability to kick-start the cleansing process that otherwise can take up to eighteen hours of fasting for the body to begin by itself. The studies to date have shown that when curcumin is highly ‘bio-available’ - present in the bloodstream in potent amounts for a long-enough period of time – it can help autophagy start much sooner. Biocurcumax is a food supplement designed to allow active curcumin to be retained in the body for more than 8 hours.
Suphil Philipose, of BioTurm, the UK distributor of Biocurcumax says: "Research has already shown that highly bio-available curcumin, when combined with the essential oil of turmeric, can stop the progressive build-up of neurologically-damaging substances. This new research opens up a new world of hope to millions of people.”
Research conducted with the University of Rome in 2015 showed Biocurcumax was able to reverse the dysfunction that sometimes occurs in autophagy, the self-cleansing process.
New studies at the University of Warwick will now seek to show the actual extent to which curcumin and pomegranates can induce autophagy and remove the damaged cells. Should these prove successful, they will progress to a human clinical trial to demonstrate the efficacy of the solution.
Crucially curcumin is thought to also have a positive effect on apoptosis - the normal, controlled death of billions of cells in the adult body every day. Curcumin also restores and maintains a healthy mitochondria, the 'battery unit' of every cell.
Philipose adds: “Nature provides us with curcumin and pomegranates that can be used as hacks to induce and kick start the self-cleansing mechanism in the body. Adjunct to a fasting diet, we may have a pathway for preventing the disease.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance